A phase 1/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC).

Authors

Andrew Peter Dean

St. John of God Hospital, Subiaco, Australia

Andrew Peter Dean , Zev A. Wainberg , Ramesh K. Ramanathan , Patrick McKay Boland , Kabir Mody , Bin Zhang , Bruce Belanger , Floris A de Jong , Stephan Braun

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 Gastrointestinal Cancers Symposium

bookmark_border

A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC).

First Author: Andrew Dean

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).

First Author: Benedikt Westphalen

insert_chart_outlined

Poster

2017 Gastrointestinal Cancers Symposium

bookmark_border

Preclinical antitumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) and utilization as a foundation of front-line pancreatic cancer regimens.

First Author: Daniel F. Gaddy

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluorouracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).

First Author: Florian Gebauer